Conventionally, CAR T therapy has demonstrated remarkable success in treating blood cancers such as leukemia and lymphoma by targeting specific, well-defined surface antigens like CD19 on malignant B cells. However, the extension of this approach to solid tumors has been thwarted by two critical hurdles: the lack of a consistently expressed surface antigen across tumor cells and the presence of a dense, immunosuppressive stroma composed of fibroblasts and myeloid cells that inhibit T cell infiltration and function. The new strategy presented by MSK researchers innovatively circumvents these barriers by targeting uPAR, a receptor highly expressed not only on malignant tumor cells but also on the supportive non-malignant cells within the tumor microenvironment.

uPAR is a cell surface receptor implicated in processes related to wound healing and tissue remodeling. In healthy tissues, its expression is limited primarily to myeloid immune cells; however, in the cancerous state, both tumor cells and the adjacent supportive niche cells abnormally upregulate uPAR. This upregulation signifies cellular states associated with malignancy, plasticity, fibrosis, and immunosuppression, thus marking uPAR as a pivotal molecule that orchestrates the tumor’s ecosystem. By leveraging this attribute, the MSK team designed CAR T cells that recognize and eradicate uPAR-positive cells, effectively dismantling the tumor itself and its protective microenvironment concurrently.

The preclinical evaluations, meticulously conducted through an array of cancer cell cultures, xenograft models harboring human tumors, and murine systems mimicking metastasis, demonstrated compelling evidence of the therapeutic potential of these uPAR-directed CAR T cells. Notably, in murine models of ovarian cancer, a notoriously therapy-resistant malignancy, these engineered T cells achieved the remarkable feat of eradicating metastatic lesions, eliciting sustained remission states. Furthermore, the persistence of these CAR T cells provided immunity against tumor rechallenge, highlighting the durability of the antitumor response.

The researchers also illuminated the utility of employing uPAR-targeted CAR T cells as adjunctive therapy post-surgical tumor debulking. In models where surgery alone rendered only temporary disease control, the administration of the CAR T cells significantly eliminated residual cancerous cells, proposing a paradigm shift in integrating cellular therapies with conventional surgical interventions to enhance long-term outcomes.

A profound insight into the molecular underpinnings of uPAR overexpression revealed a correlation with mutations in key oncogenes and tumor suppressors, including p53 and KRAS—mutations frequently encountered in aggressive and treatment-resistant cancers. This molecular association underscores the potential of uPAR-targeted therapy to address hard-to-treat cancers by attacking a common vulnerability linked to critical pathways driving malignancy and cellular plasticity.

Interestingly, the team capitalized on combining the uPAR CAR T cells with senescence-inducing chemotherapeutic agents such as cisplatin, which heighten uPAR expression on tumor cells, thereby enhancing the CAR T cells’ recognition and cytotoxicity. This combinatorial approach not only amplifies therapeutic efficacy but also exploits the dynamic changes within the tumor cell population induced by chemotherapy, addressing cancer’s notorious adaptability.

The innovation extends to molecular engineering sophistication: the designers selected uPAR binders that specifically target a form of the receptor less prone to being shed from the cell surface due to inflammatory signals. This specificity ensures sustained CAR T cell engagement, thereby optimizing the cytotoxic effect and circumventing a common mechanism by which tumors evade immune surveillance.

Crucially, this therapy’s dual-targeting capacity extends beyond malignant cells to encompass tumor-associated fibroblasts and immunosuppressive myeloid cells within the tumor microenvironment. This approach disrupts the cancer-supportive niche—a complex tissue landscape that enables tumor growth, immune evasion, and therapeutic resistance—introducing a multifaceted assault on the tumor ecosystem rather than a unidimensional attack on tumor cells alone.

The conceptual framework of this research is deeply rooted in viewing cancer through the lens of systems biology, recognizing tumors as dynamic ecosystems constituted by cancer cells and their intricate interactions with surrounding stroma and immune cells. Such an ecosystem-centered outlook empowers the development of interventions aimed at perturbing these critical intercellular networks, exemplified by the uPAR-targeted CAR T cells. This strategy reflects the paradigm of the Marie-Josée and Henry R. Kravis Cancer Ecosystems Project at MSK, which promotes innovative therapies by dissecting and targeting these interconnected cellular systems.

Beyond its applications in oncology, the therapeutic implications of targeting uPAR-positive cells extend to various fibrotic, inflammatory, and degenerative diseases wherein similar pathological cell types contribute to disease progression. Therefore, therapies built upon this foundation promise broader biomedical applications, opening new frontiers in treating diseases characterized by aberrant tissue remodeling and inflammation.

Monitoring the disease burden and therapeutic efficacy also benefits from the identification of uPAR-related biomarkers. The team demonstrated the potential of measuring soluble uPAR (suPAR) fragments in the bloodstream and utilizing uPAR-targeted positron emission tomography (PET) imaging to non-invasively visualize tumor presence and treatment response, which could revolutionize real-time disease surveillance and personalized medicine approaches.

The discovery and development of uPAR-targeted CAR T cells signify not only a technical tour de force in immunoengineering but also a conceptual leap in treating solid tumors by simultaneously targeting both the cancer cells and their supportive milieu. As this therapy progresses toward clinical evaluation, it heralds a potentially transformative advancement in cancer treatment modalities, offering hope for overcoming long-standing obstacles in solid tumor immunotherapy.

Subject of Research:
Article Title: A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
News Publication Date: 30-Mar-2026
Web References: https://www.cell.com/cell/fulltext/S0092-8674(26)00269-2, https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy/car-cell-therapy
References: DOI: 10.1016/j.cell.2026.03.002
Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: CAR T cell therapy, uPAR, tumor microenvironment, solid tumors, immunotherapy, cancer biology, cellular senescence, tumor ecosystem, metastatic cancer, molecular oncology, immunoengineering, targeted therapy

One of the most promising developments presented was the initial data from the phase 1 clinical trial of izalontamab brengitecan (iza-bren/BL-B01D1), an experimental bispecific antibody-drug conjugate (ADC). This innovative molecule uniquely targets tumor cells harboring mutations in both the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) genes. Unlike conventional ADCs, which typically latch onto a single mutation, iza-bren’s dual targeting mechanism allows it to deliver chemotherapy directly to cancerous cells expressing either mutation, enhancing selectivity and potentially improving efficacy.

The trial, conducted at 22 locations across the United States with Dr. Helena Yu as principal investigator at MSK, has so far enrolled 107 patients with advanced solid tumors, prominently non-small cell lung cancer (NSCLC). Among the subgroup of 10 NSCLC patients who received the optimal dose, an impressive 75% showed tumor shrinkage, indicating a robust response to the therapy. While the most prevalent adverse effects were manageable cytopenias, their treatability renders the drug’s safety profile encouraging as trial enrollment continues with plans for extended investigations.

In the realm of pancreatic cancer, MSK’s phase 1 trial SHARON addressed a particularly refractory subset of patients: those with advanced disease driven by inherited mutations in BRCA1/2 or PALB2 genes. These genetic aberrations confer increased therapeutic resistance, exhausting standard chemotherapy options. The SHARON trial combines targeted chemotherapy regimens with autologous stem cell transplantation, a sophisticated approach wherein patients’ own hematopoietic stem cells are harvested prior to chemotherapy and then reinfused post-treatment to aid marrow recovery.

This innovative protocol was presented by Dr. Kenneth Yu and is jointly conducted with Massachusetts General Hospital, reflecting an interdisciplinary collaboration. Interim findings in 11 patients with stage 3 pancreatic cancer displaying hereditary mutations revealed a median progression-free interval of 14.2 months among those with disease control. Remarkably, two patients remained disease-free at 23 and 48 months post-therapy, with no unexpected toxicities reported. These encouraging outcomes have prompted plans to expand enrollment, aiming to refine safety and efficacy parameters further.

Delving deeper into tumor biology, MSK researchers shed light on the complexities of mismatch repair deficiency (MMRd) and microsatellite instability-high (MSI-H) conditions. Both genetic phenomena are pivotal in predicting responsiveness to immune checkpoint inhibitors—therapies that have transformed the landscape of cancer immunotherapy. However, the new research, spearheaded by Dr. Benoît Rousseau and presented by Dr. Violaine Randrian, reveals that the specific mechanisms inciting MMRd or MSI-H have a significant impact on therapeutic success and patient survival rates.

By analyzing an extensive dataset comprising nearly 2,000 MSK patients alongside an external commercial laboratory database surpassing 13,000 individuals, the team correlated immunotherapy outcomes with tumor types and underlying genetic mechanisms for mismatch repair defects. Their findings emphasize that inherited conditions such as Lynch syndrome and tumors exhibiting true MSI-H are associated with more durable responses and favorable survival, suggesting the necessity for nuanced molecular diagnostics to tailor immunotherapeutic regimens accurately.

Adding to the arsenal against MSI-H/MMRd tumors, MSK investigators introduced preliminary findings from a first-in-human phase 1 study of HRO761, a novel targeted agent designed to inhibit Werner helicase, a DNA repair enzyme critical for maintaining genomic stability in cancer cells. Dr. Michael Foote presented data involving 57 patients with advanced solid tumors refractory to prior immunotherapies, chemotherapies, or targeted drugs. HRO761 demonstrated a notable disease control rate of nearly 80% in colorectal cancer patients, with around 70% exhibiting clearance of circulating tumor DNA within one month, marking a formidable early proof-of-concept.

Importantly, the safety profile of HRO761 was favorable, with no treatment discontinuations due to adverse events, underscoring its potential in overcoming resistance mechanisms in MSI-H/MMRd malignancies. Ongoing dose-escalation and combination studies aim to elucidate optimal therapeutic use, paving the way for potential integration into standard care frameworks pending confirmatory efficacy data.

Collectively, these multifaceted investigations highlighted at ESMO 2025 underscore MSK’s commitment to pioneering personalized and precision oncology, leveraging genetic insights and novel therapeutic platforms to tackle historically intractable cancers. From bispecific ADCs revolutionizing lung cancer treatment paradigms to leveraging hematopoietic stem cell transplantation in genotypically defined pancreatic cancer, and refining immunotherapy based on mechanistic subtleties of mismatch repair deficiencies, these studies represent a watershed moment in cancer research.

These advances also exemplify the critical importance of collaborative clinical trials and integrative research approaches, which are essential for translating molecular discoveries into tangible patient benefits. The emerging data not only inspire optimism for improved survival and quality of life but also set the stage for further inquiries into combinatorial and mechanistically tailored interventions.

As MSK and their partners continue to enroll patients and refine these therapies, the oncology field watches closely, recognizing that such innovations could redefine treatment algorithms and offer hope to patients with few remaining options. Precision targeting of cancer vulnerabilities at the molecular and genetic levels, as demonstrated in these forefront studies, is poised to transform standard-of-care paradigms and manifestations of personalized medicine.

The presentations and ongoing studies highlight an era of cancer treatment characterized by both technological ingenuity and deep biological understanding. By exploiting dual mutation targeting, integrating stem cell support with chemotherapy, and unearthing how genetic mechanisms influence therapy response, MSK’s research at ESMO 2025 exemplifies the future of oncology—where treatments are no longer one-size-fits-all but strategically designed to outsmart tumors at their unique molecular weaknesses.

Subject of Research: Innovative therapies for advanced solid tumors and insights into mismatch repair deficiency-related cancers.

Article Title: Memorial Sloan Kettering’s Breakthrough Studies Redefine Treatment and Understanding of Advanced Solid Tumors at ESMO 2025

News Publication Date: October 2025

Web References:

• MSK Lung Cancer
• MSK Pancreatic Cancer
• MSK Iza-bren Phase 1 Study
• MSK SHARON Trial
• MSK MMRd and MSI-H Research
• MSK HRO761 Phase 1 Study

References: Information derived from MSK presentations and clinical trial data at ESMO Congress 2025.

Keywords: Advanced solid tumors, non-small cell lung cancer, pancreatic cancer, bispecific antibody-drug conjugate, immunotherapy, mismatch repair deficiency, microsatellite instability, targeted therapy, stem cell transplant, clinical trials.